During the past decade, Alexander Schulze - Germany conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Alexander Schulze - Germany" are "Depressive Disorder, Major" (1 trials) and "Depressive Disorder, Treatment-Resistant" (1 trials). Many other conditions were trialed in "Alexander Schulze - Germany" in a lesser frequency.

Most popular intervention types in "Alexander Schulze - Germany" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Esketamine 28 mg" (1 trials), "Esketamine 56 mg" (1 trials), "Esketamine 84 mg" (1 trials), "Quetiapine XR 100 mg" (1 trials) and "Quetiapine XR 150 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Alexander Schulze - Germany" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Alexander Schulze - Germany". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Alexander Schulze - Germany, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Alexander Schulze - Germany, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".